Last updated: September 24, 2026
Quadramet, the trade name for samarium Sm-153 lexidronam injection, is a discontinued radiopharmaceutical for palliative relief of pain from osteoblastic bone metastases. Its commercial decline resulted from a combination of limited clinical positioning, nuclear-medicine manufacturing constraints, competition from newer oncology therapies, and the absence of a durable exclusivity platform. Public filings do not disclose standalone Quadramet revenue, and the product does not have a current commercial growth profile comparable with active oncology radiopharmaceuticals such as Xofigo.
What is Quadramet and what was it approved to treat?
Quadramet contains samarium Sm-153 lexidronam, a bone-seeking radiopharmaceutical. The lexidronam ligand concentrates in areas of increased osteoblastic activity, while Sm-153 emits beta radiation intended to reduce metastatic bone pain. It also emits gamma radiation, allowing post-administration imaging and creating handling requirements for nuclear-medicine departments.
The FDA approved Quadramet in 1997 for the relief of pain in patients with osteoblastic metastatic bone lesions that enhance on technetium-99m bone scans. The product was palliative rather than disease-modifying. It did not treat the underlying cancer or demonstrate the type of survival benefit that later became central to oncology drug adoption and reimbursement decisions.[1]
What was the approved dosage form?
Quadramet was supplied as a sterile intravenous injection containing samarium Sm-153 lexidronam. Dosing was based on patient weight and administered through a nuclear-medicine facility. The product required radiation-safety controls, specialist personnel, dose calibration, and coordinated delivery from a radiopharmaceutical supplier.
The short physical half-life of Sm-153, approximately 46 hours, limited inventory flexibility. Production, quality release, shipment, and administration had to be coordinated within a narrow time window.[1]
When did Quadramet lose exclusivity and commercial momentum?
Quadramet’s primary commercial exclusivity began with its 1997 FDA approval and was effectively exhausted well before the product’s later market decline. Any conventional small-molecule patent protection associated with the original product would generally have been subject to the 20-year patent term measured from the relevant U.S. filing date, adjusted for patent-term restoration where applicable.
The key commercial milestones were:
| Milestone |
Date |
Commercial significance |
| FDA approval of Quadramet |
1997 |
Established the product as a palliative radiopharmaceutical for osteoblastic bone pain |
| FDA approval of Metastron, strontium-89 chloride |
1990s |
Created an established competing radiopharmaceutical option |
| FDA approval of Xofigo, radium Ra-223 dichloride |
2013 |
Added an oncology radiopharmaceutical with a disease-specific prostate-cancer indication |
| Later commercial discontinuation |
FDA-listed as discontinued |
Removed Quadramet from the active commercial product base |
The exact loss of commercial exclusivity is less important than the later absence of a protected, actively promoted market. Quadramet was a mature product with a narrow palliative indication. Its economic value depended on reliable isotope supply and treatment-center utilization rather than on continuing patent exclusivity.
What is the FDA regulatory status of Quadramet?
The FDA’s Drugs@FDA materials identify Quadramet as an approved product with discontinued marketing status. Discontinued marketing does not, by itself, establish that FDA withdrew the product for safety or efficacy reasons. It indicates that the product is no longer actively marketed under the relevant application.[2]
Quadramet does not have the regulatory profile of an active branded oncology product. The principal regulatory issues are:
- discontinued commercial distribution;
- radioactive-material handling requirements;
- dependence on specialized nuclear pharmacies or radiopharmaceutical suppliers;
- limited substitution options because radiopharmaceutical production is not equivalent to conventional generic tablet or injectable manufacturing;
- the need for a sponsor to maintain approved chemistry, manufacturing, and controls data.
Is Quadramet listed in the Orange Book?
The Orange Book is primarily relevant to active approved products and their listed patents and exclusivities. Public FDA materials do not identify a current active Orange Book patent or exclusivity position that would protect ongoing Quadramet sales.
The absence of a current Orange Book barrier means that a future sponsor would not face a conventional brand-patent wall comparable with those affecting major oral oncology drugs. The practical barrier would instead be regulatory redevelopment, isotope supply, manufacturing validation, distribution infrastructure, and treatment-center economics.[2,3]
What patents protect Quadramet?
Quadramet’s original protection was associated with the samarium-153 lexidronam composition, its formulation, and the use of bone-seeking radiopharmaceutical therapy for metastatic lesions. No active, commercially material patent estate is identified in current FDA materials for Quadramet.
How strong is the Quadramet patent estate?
The current patent estate is weak as a commercial defense. The product was approved in 1997, and the conventional patent life associated with a product of that age would have largely expired by the time the market began facing newer radiopharmaceutical competition.
Patent strength can be assessed across four categories:
| Patent category |
Current commercial relevance |
| Active ingredient or chelate composition |
Limited; product age makes remaining protection unlikely to block ordinary competition |
| Formulation patents |
Limited; no current FDA-listed formulation barrier identified |
| Method-of-use patents |
Limited; palliative treatment of osteoblastic bone pain is a mature use |
| Manufacturing or isotope-production patents |
Potentially relevant to process economics, but unlikely to recreate broad product exclusivity |
Manufacturing know-how may still have value. A supplier that controls reliable Sm-153 production, chelation, sterility testing, dose calibration, and just-in-time distribution can create a practical market advantage even without an enforceable product patent.
Were there Paragraph IV challenges to Quadramet?
No material Paragraph IV challenge is identified in the cited public FDA materials. That outcome is consistent with the product’s commercial structure. Quadramet was a radiopharmaceutical injection with specialized production and limited market scale, not a high-volume conventional generic opportunity.
A Paragraph IV filing would have been less attractive because:
- the product required radioactive isotope production;
- demand was concentrated in specialized oncology and nuclear-medicine centers;
- the market faced competing radiopharmaceutical and non-radiopharmaceutical treatments;
- commercial supply depended on short-lived inventory;
- a generic entrant would still need to establish a reliable isotope and distribution network.
Does Quadramet face biosimilar risk?
No. Quadramet is a chemically defined radiopharmaceutical, not a biologic. Biosimilar litigation and interchangeable-biologic substitution rules do not apply. Any successor product would use an abbreviated or full drug-approval strategy appropriate to the FDA’s treatment of the specific product, not the Public Health Service Act biosimilar pathway.
What formulations are protected by Quadramet patents?
No currently active, commercially meaningful formulation patent is identified for Quadramet. The product’s technical differentiation came from the samarium-153 radionuclide, lexidronam chelation, sterile injectable presentation, and manufacturing controls rather than from a modern extended-release or delivery-system platform.
The principal technical barriers were operational:
- stable chelation of the radioactive isotope;
- control of radiochemical purity;
- sterility and endotoxin compliance;
- dose activity calibration at release and administration;
- radioactive shipping and handling;
- synchronization of production with clinical use.
These barriers can deter entrants but do not provide the same legal exclusivity as a live composition-of-matter or formulation patent.
What patent litigation affects Quadramet?
No significant current patent litigation involving Quadramet is identified in the cited FDA and public regulatory sources. The product has not generated a current litigation profile comparable with high-revenue oncology brands facing Paragraph IV suits, patent-term disputes, or settlement agreements.
No material Quadramet-specific patent settlement agreement is identified in the cited record. The commercial issue is product availability and replacement, not an active infringement dispute.
How did Quadramet’s market dynamics change?
Quadramet entered a market in which treatment was primarily palliative. Its value proposition was strongest for patients with painful, osteoblastic bone metastases who required systemic pain relief and had limited alternatives.
The market weakened for several reasons.
Competition from other radiopharmaceuticals
Strontium-89 chloride, marketed as Metastron, was an earlier systemic radiopharmaceutical for painful bone metastases. It competed directly for treatment-center capacity and physician familiarity.
Xofigo, approved in 2013 for certain patients with metastatic castration-resistant prostate cancer and symptomatic bone metastases, changed the competitive framework. Xofigo was associated with a disease-specific treatment strategy and survival data, rather than pain palliation alone.[4]
Expansion of disease-modifying cancer therapy
Improved use of androgen-receptor pathway inhibitors, taxanes, bone-targeted therapies, and other systemic oncology treatments changed the management of metastatic cancer. Pain palliation remained clinically relevant, but the treatment decision increasingly depended on sequencing with therapies that affected tumor progression or survival.
Nuclear-medicine supply constraints
Quadramet’s commercial model required isotope production and rapid distribution. Sm-153 availability depended on reactor capacity, precursor supply, processing capability, and logistics. Any interruption could affect treatment schedules and weaken physician confidence.
The product also required hospitals to maintain radiation-safety infrastructure and nuclear-medicine expertise. Those requirements limited broad community adoption.
What was Quadramet’s financial trajectory?
No public filing provides a reliable standalone revenue series for Quadramet. Historical sales were reported within broader company or product portfolios, and later corporate ownership changes make product-level reconstruction difficult.
The financial trajectory can therefore be described qualitatively:
| Period |
Financial profile |
| Post-approval period |
Specialty radiopharmaceutical revenue supported by an approved palliative indication |
| Mature commercial period |
Limited growth, with demand tied to bone-metastasis incidence, treatment-center access, and isotope supply |
| Competitive pressure period |
Margin and volume pressure from competing radiopharmaceuticals and changing oncology standards |
| Discontinuation period |
Revenue declined to zero or immaterial levels under the relevant commercial product portfolio |
Quadramet’s economics were structurally less attractive than those of high-volume oral oncology products. Revenue was constrained by:
- a narrow patient population;
- one-time or intermittent administration;
- hospital-based delivery;
- short product shelf life;
- high distribution complexity;
- limited pricing leverage for a palliative indication;
- competition from both radiopharmaceuticals and conventional systemic therapies.
The product also lacked a durable recurring-revenue model. Patients generally received treatment for symptom control rather than ongoing monthly or daily therapy. That limited lifetime revenue per patient and increased dependence on new patient flow.
Which companies challenged or replaced Quadramet?
No current company is identified as challenging Quadramet through a conventional generic litigation strategy. Competitive pressure came from alternative products and treatment modalities.
| Competitor or alternative |
Category |
Competitive effect |
| Metastron, strontium-89 chloride |
Radiopharmaceutical |
Direct alternative for painful bone metastases |
| Xofigo, radium Ra-223 dichloride |
Therapeutic radiopharmaceutical |
Offered a disease-specific prostate-cancer treatment with survival-related clinical positioning |
| Bisphosphonates |
Bone-targeted therapy |
Reduced skeletal complications and supported broader metastatic bone-disease management |
| Denosumab |
RANK ligand inhibitor |
Competed in prevention of skeletal-related events |
| Opioid and non-opioid analgesics |
Symptom management |
Provided lower-complexity pain-control alternatives |
| Systemic anticancer therapies |
Disease-modifying treatment |
Reduced reliance on stand-alone palliative radiopharmaceutical treatment |
Xofigo was not a direct substitute for every Quadramet patient because its approved indication was narrower. Its commercial significance came from demonstrating the market’s movement toward radiopharmaceuticals with disease-specific clinical development and survival-oriented positioning.[4]
What generic launch risks exist for Quadramet?
A future entrant would face lower patent risk but high execution risk. The principal launch scenarios are:
Scenario 1: No commercial re-entry
This is the most straightforward outcome when expected demand does not justify isotope-production and regulatory costs. The market remains served by alternative radiopharmaceuticals, systemic therapies, and pain management.
Scenario 2: Limited specialty reintroduction
A radiopharmaceutical manufacturer could reintroduce a samarium-153 lexidronam product for selected nuclear-medicine centers. Commercial success would depend on securing isotope supply and obtaining sufficient reimbursement.
Scenario 3: Hospital or regional supply model
A regional nuclear pharmacy or hospital network could pursue a limited distribution strategy. This would reduce national commercial overhead but would not eliminate FDA, radiation-safety, quality, and logistics requirements.
Scenario 4: Repositioned radiopharmaceutical platform
A sponsor could use Sm-153 or another isotope in a broader targeted-radiopharmaceutical platform. That strategy would rely on new clinical evidence and would compete against newer alpha- and beta-emitting agents rather than simply revive the legacy Quadramet brand.
How does Quadramet compare with Xofigo?
| Attribute |
Quadramet |
Xofigo |
| Active ingredient |
Samarium Sm-153 lexidronam |
Radium Ra-223 dichloride |
| FDA approval |
1997 |
2013 |
| Primary role |
Pain relief for osteoblastic bone metastases |
Treatment of specific metastatic castration-resistant prostate cancer patients |
| Disease modification |
Palliative |
Developed with disease-control and survival objectives |
| Radiation type |
Beta emission with gamma emission |
Alpha emission |
| Commercial status |
Discontinued |
Active branded product subject to its own commercial and regulatory status |
| Patent position |
Mature or expired protection profile |
Later-generation patent and regulatory framework |
| Main barrier |
Isotope production and distribution |
Specialized manufacturing, clinical positioning, and regulatory exclusivity |
Quadramet had broader palliative applicability in one respect but weaker disease-specific commercial positioning. Xofigo benefited from a later development era in which oncology radiopharmaceuticals were evaluated as part of treatment strategy rather than primarily as pain-control products.
What geographic coverage did Quadramet have?
Quadramet was primarily relevant to markets with:
- FDA or comparable regulatory approval;
- nuclear-medicine treatment centers;
- licensed radioactive-material facilities;
- isotope production and transport infrastructure;
- reimbursement for hospital-administered radiopharmaceuticals.
Its geographic reach was limited by the short half-life of Sm-153 and the requirement for controlled transport. A country could not support meaningful use merely by approving the product; it also needed dependable local or regional isotope logistics.
The United States was the principal reference market for the FDA-approved product. The commercial opportunity in other jurisdictions depended on separate regulatory approvals, local manufacturing arrangements, reimbursement, and radiation-safety rules.
What manufacturing and intellectual-property barriers remain?
The remaining barriers are mainly technical and regulatory rather than patent-based.
A viable supplier would need:
- access to a qualified source of Sm-153;
- validated production of samarium-153 lexidronam;
- sterile and radiochemical manufacturing capability;
- quality systems suited to short-lived radioactive products;
- licensed radioactive-material facilities;
- dose-calibration and release procedures;
- validated packaging and transport;
- hospital and nuclear-pharmacy distribution relationships.
These requirements can protect incumbent capability without creating legally enforceable exclusivity. They also raise the fixed cost of market entry relative to the size of the patient population.
Key Takeaways
- Quadramet is samarium Sm-153 lexidronam, an FDA-approved palliative radiopharmaceutical for painful osteoblastic bone metastases.
- FDA approval occurred in 1997, and the product is now listed as discontinued.
- No current material Orange Book patent or regulatory-exclusivity barrier is identified.
- No significant Paragraph IV challenge, biosimilar issue, patent litigation, or settlement agreement is identified for the product.
- Public filings do not provide a reliable standalone Quadramet revenue history.
- Commercial decline reflected limited palliative demand, isotope-supply constraints, specialized distribution, and competition from newer oncology therapies.
- The principal barriers to re-entry are manufacturing, radioactive logistics, regulatory approval, reimbursement, and treatment-center utilization.
- Xofigo represents a later-generation competitor with a more disease-specific and survival-oriented clinical position.
- Any future Quadramet-like product would need to compete on supply reliability, clinical evidence, reimbursement, and integration with modern cancer treatment.
FAQs
Is Quadramet still available in the United States?
No active commercial availability is identified in FDA materials. Quadramet is listed with discontinued marketing status.
Can a generic manufacturer launch Quadramet without a patent license?
Patent barriers appear limited, but a manufacturer would still need FDA approval, qualified isotope supply, radiopharmaceutical manufacturing capability, and compliant radioactive distribution.
Is Quadramet interchangeable with Xofigo?
No. The products use different radionuclides, have different clinical development programs, and do not have identical FDA indications.
Did Quadramet generate blockbuster revenue?
No public evidence supports blockbuster-level standalone revenue. The product served a narrow, hospital-based palliative market and lacked the recurring-use profile of major chronic oncology drugs.
Could samarium-153 support a new radiopharmaceutical franchise?
Potentially, but a new franchise would require a differentiated clinical indication, reliable isotope supply, modern clinical evidence, reimbursement support, and a regulatory strategy beyond simply reviving the discontinued brand.
References
-
U.S. Food and Drug Administration. (1997). Quadramet (samarium Sm-153 lexidronam injection) prescribing information.
-
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs, Quadramet.
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book.
-
U.S. Food and Drug Administration. (2013). Xofigo (radium Ra-223 dichloride) prescribing information.
